Paclitaxel and Cisplatin for Thymic Neoplasm
To assess the efficacy and safety of the regimen in previously untreated, unresectable invasive thymoma or thymic carcinoma
Thymoma|Thymic Carcinoma
DRUG: paclitaxel and cisplatin
Response rate, 6 weeks, 12 weeks, 18 weeks
toxicity, start of medication to 4 weeks since the last medication|progression-free survival, till progression|duration of response, till progression|overall survival, till death, last follow-up
To assess the efficacy and safety of the regimen in previously untreated, unresectable invasive thymoma or thymic carcinoma